A directory of where to buy chemicals in the USA, including: distributors, industrial manufacturers, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the suppliers website for prices or more information.
| Product | Description | |
|---|---|---|
| GSK-2881078 | GSK-2881078 is an orally active and nonsteroidal selective androgen receptor modulator (SARM) which act as partial AR agonists in androgenic tissues while mainly as complete AR agonists in synthetic metabolic tissues,induces AR-mediated transcriptional activation in PC3(AR)2 cells (EC50 = 3.99 nM) and the effect can be inhibited by the non-steroidal AR antagonist Bicalutamide. GSK-2881078 can be used in research of muscle weakness and cachexia associated with both chronic and acute illness[1][2][3][4]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1539314-06-1. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-100186. |  |
| GSK-2881078 | GSK-2881078, an indole derivative, has been found to be an androgen receptor modulator that could probably be effective against Cachexia. It is still under Phase I trail. Uses: Anabolic agents. Synonyms: GSK 2881078; GSK2881078; CS-5736; (R)-1-(1-(methylsulfonyl)propan-2-yl)-4-(trifluoromethyl)-1H-indole-5-carbonitrile. Grade: 98%. CAS No. 1539314-06-1. Molecular formula: C14H13F3N2O2S. Mole weight: 330.33. |  |
| GSK-2894631A | GSK2894631A is an inhibitor of hematopoietic PGD synthase (HPGDS). Synonyms: HPGDS inhibitor 2. CAS No. 2101626-26-8. Molecular formula: C20H24F2N2O3. Mole weight: 378.4. | |
| GSK2982772 | GSK2982772, with potential effect to treat inflammatory diseases, potently binds to RIP1 with exquisite kinase specificity. In phase 2a clinical studies for psoriasis, rheumatoid arthritis, and ulcerative colitis. Synonyms: GSK2982772; GSK 2982772; GSK-2982772; 5-benzyl-N-[(3S)-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-1H-1,2,4-triazole-3-carboxamide. CAS No. 1622848-92-3. Molecular formula: C20H19N5O3. Mole weight: 377.4. | |
| GSK2982772 | GSK2982772 is a potent, orally active and ATP competitive RIP1 kinase inhibitor with IC50 values of 16 nM and 20 nM for human and monkey RIP1, respectively[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1622848-92-3. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-101760. | |
| GSK2983559 | GSK2983559 is a potent, selective and oral active inhibitor of receptor interacting protein 2 (RIP2) kinase. GSK2983559 exhibits activity in blocking many proinflammatory cytokine responses in vivo and in human inflammatory bowel disease explant samples. Synonyms: RIP2 kinase inhibitor 1; RIPK2-IN-1; GSK-2983559; GSK 2983559. CAS No. 1579965-12-0. Molecular formula: C21H23N4O7PS2. Mole weight: 538.53. | |
| GSK2983559 active metabolite | GSK2983559 active metabolite is an active metabolite of GSK2983559. GSK2983559 active metabolite is a receptor interacting protein-2 (RIP2) kinase inhibitor extracted from patent WO/2014043446 A1, compound example 1. Uses: Scientific research. Category: Signaling pathways. CAS No. 1423186-80-4. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-19764. | |
| GSK299115A | GSK299115A is a G-Protein-Coupled Receptor Kinase 2 (GRK2) Inhibitor. Synonyms: GSK299115A; GSK 299115A; GSK-299115A. 4-(3,4-dichlorophenyl)-N-(1H-indazol-5-yl)-6-methyl-2-oxo-3,4-dihydro-1H-pyridine-5-carboxamide. Grade: 98%. CAS No. 864082-35-9. Molecular formula: C20H16Cl2N4O2. Mole weight: 415.27. | |
| GSK299423 | GSK299423 is an antibiotic agent and it seems potentially effective in treating patients infected with bacteria expressing the New Delhi metallo-beta-lactamase. GSK299423 is a Type II bacterial DNA topoisomerase inhibitor under the development of GlaxoSmithKline. Early research for the treatment of Gram-negative infections and Nosocomial infections was on-going in USA. Uses: Gram-negative infections; nosocomial infections. Synonyms: GSK299423; GSK 299423; GSK-299423; 4-(2-(4-(([1,3]oxathiolo[5,4-c]pyridin-6-ylmethyl)amino)piperidin-1-yl)ethyl)-6-methoxyquinoline-3-carbonitrile. Grade: 98%. CAS No. 1352149-24-6. Molecular formula: C25H27N5O2S. Mole weight: 461.58. | |
| GSK3004774 | GSK3004774 is a potent, nonabsorbable, gastrointestinally-restricted CaSR agonist, with an EC50 of 50 nM for human and pEC50s of 7.3, 6.6 and 6.5 for human, mouse and rat, respectively. Synonyms: 1-[3-({4-[(3R)-3-{[(1S)-1-(1-Naphthyl)ethyl]amino}-1-pyrrolidinyl]benzoyl}amino)propyl]-4-piperidinecarboxylic acid; 4-Piperidinecarboxylic acid, 1-[3-[[4-[(3R)-3-[[(1S)-1-(1-naphthalenyl)ethyl]amino]-1-pyrrolidinyl]benzoyl]amino]propyl]-. Grade: ≥97%. CAS No. 2138814-32-9. Molecular formula: C32H40N4O3. Mole weight: 528.69. | |
| GSK 3008348 | GSK 3008348 is a small molecule antagonist of integrin αvβ6 with IC50 values for αvβ6, αvβ1, αvβ3, αvβ5, and αvβ8 are 1.50, 2.83, 12.53, 4.00, and 2.26 nM, respectively. GSK 3008348 can target the αvβ6 integrin, inhibit TGF-β activation, and thereby alleviate the fibrotic process. GSK 3008348 prevents the binding of the foot-and-mouth disease virus (FMDV) to the αvβ6 integrin receptor on the surface of host cells, thereby inhibiting the entry of the virus. GSK 3008348 can be used for research on pulmonary fibrosis and various types of cancer[1][2][3][4]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1629249-33-7. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 1 g. Product ID: HY-19767. | |
| GSK-3008348 | GSK-3008348 is an integrin αvβ6 antagonist developed for the treatment of idiopathic pulmonary fibrosis (IPF). Synonyms: GSK 3008348; GSK3008348. Grade: 98% by HPLC. CAS No. 1629249-33-7. Molecular formula: C29H38ClN5O2. Mole weight: 524.1. | |
| GSK 3008348 hydrochloride | GSK 3008348 hydrochloride is a small molecule antagonist of integrin αvβ6 with IC50 values for αvβ6, αvβ1, αvβ3, αvβ5, and αvβ8 are 1.50, 2.83, 12.53, 4.00, and 2.26 nM, respectively. GSK 3008348 hydrochloride can target the αvβ6 integrin, inhibit TGF-β activation, and thereby alleviate the fibrotic process. GSK 3008348 hydrochloride prevents the binding of the foot-and-mouth disease virus (FMDV) to the αvβ6 integrin receptor on the surface of host cells, thereby inhibiting the entry of the virus. GSK 3008348 hydrochloride can be used for research on pulmonary fibrosis and various types of cancer[1][2][3]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1629249-40-6. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-19767A. | |
| GSK3117391 | GSK3117391 (ESM-HDAC391; CHR-5154; HDAC-IN-3) is an orally active HDAC inhibitor with a IC50 of 55 nM. Using esterase-sensitive motif technology, GSK3117391 is selectively converted into its active acid metabolite HDAC189 in cells expressing carboxylesterase-1. GSK3117391 induces sustained global protein acetylation in monocytes, inhibits the production of proinflammatory cytokines, depletes circulating monocytes, downregulates the expression of CSF1R, and inhibits monocyte adhesion and differentiation. GSK3117391 can be used in the research of chronic inflammatory diseases[1]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: ESM-HDAC391; CHR-5154; HDAC-IN-3. CAS No. 1018673-42-1. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-19772. | |
| GSK3117391 | GSK3117391, a HDAC inhibitor, was developed by GSK considering its potential effect in the treatment of arthritis and rheumatoid. It was already being terminated the phase 1 trial. Uses: Gsk3117391, a hdac inhibitor, was developed by gsk considering its potential effect in the treatment of arthritis and rheumatoid. Synonyms: GSK3117391; GSK-3117391; GSK 3117391; GSK3117391A; GSK-3117391A; GSK 3117391A; HDAC-IN-3; SCHEMBL15144242; AFDPFLDWOXXHQM-NRFANRHFSA-N; CS-5448; HY-19772; 121555-EP2295410A1. Grade: 95%. CAS No. 1018673-42-1. Molecular formula: C22H33N3O4. Mole weight: 403.52. | |
| GSK3145095 | GSK3145095 is an orally active RIP1 kinase inhibitor with IC50 of 6.3 nM. It potently binds to RIP1 with exquisite kinase specificity and has excellent activity in blocking RIP1 kinase-dependent cellular responses. Synonyms: GSK 3145095; GSK-3145095. CAS No. 1622849-43-7. Molecular formula: C20H17F2N5O2. Mole weight: 397.38. | |
| GSK317354A | GSK317354A is a G-Protein-Coupled Receptor Kinase 2 (GRK2) inhibitor,but no detailed information has been published yet. Synonyms: GSK317354A; GSK-317354A; GSK 317354A. 4-(4-fluorophenyl)-N-(1H-indazol-5-yl)-6-methyl-2-(6-(trifluoromethyl)pyridin-3-yl)-1,4-dihydropyrimidine-5-carboxamide. Grade: 98%. CAS No. 874119-13-8. Molecular formula: C25H18F4N6O. Mole weight: 494.45. | |
| GSK-3174998 | GSK-3174998 is a humanized IgG1 OX40/TNFRSF4 agonistic monoclonal antibody. GSK-3174998 has the potential for the study of advanced solid tumors. The isotype control for GSK-3174998 can refer to Human IgG1 kappa, Isotype Control (HY-P99001)[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2089398-68-3. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P991052. | |
| GSK319347A | GSK319347A is a dual inhibitor of TBK1 and IKKε with IC50s of 93 nM and 469 nM, respectively. GSK319347A also inhibits IKK2 with an IC50 of 790 nM. Uses: Scientific research. Category: Signaling pathways. CAS No. 862812-98-4. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-14682. | |
| GSK321 | GSK321 is a highly potent, selective inhibitor of mutant IDH1 enzymes, with IC50=4.6 nM against R132H, 3.8 nM against R132C and 2.9 nM against R132G. GSK321 stably decreased 2-hydroxyglutarate (2-HG) production in several different IDH1 mutant AML cells within a 2-3 week time frame ex vivo. Because of the allosteric nature of the interaction, GSK321 is able to inhibit multiple mutant forms of IDH1, which is consistent with our cell biological observations. Furthermore, GSK321 retains excellent potency in cells, since it does not compete with the tightly bound cofactor. Synonyms: (7R)-1-[(4-fluorophenyl)methyl]-N-[3-[(1S)-1-hydroxyethyl]phenyl]-7-methyl-5-(1H-pyrrole-2-carbonyl)-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-3-carboxamide; (7R)-1-[(4-fluorophenyl)methyl]-N-[3-[(1S)-1-hydroxyethyl]phenyl]-7-methyl-5-(1H-pyrrole-2-carbonyl)-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-3-carboxamide; GSK321; GSK 321; GSK-321; BDBM195601. Grade: >98%. CAS No. 1816331-63-1. Molecular formula: C28H28FN5O3. Mole weight: 501.56. | |
| GSK321 | GSK321 is a potent, selective mutant IDH1 inhibitor with IC50 values of 2.9, 3.8, 4.6 and 46 nM for R132G, R132C, R132H and WT IDH1, respectively, and >100-fold selectivity over IDH2. GSK321 induces decrease in intracellular α-Hydroxyglutaric acid (2-HG) (HY-113038B), abrogation of the myeloid differentiation block and induction of granulocytic differentiation at the level of leukemic blasts and more immature stem-like cells. GSK321can be used for research of acute myeloid leukemia (AML) and other cancers[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1816331-63-1. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-18948. | |
| GSK329 | GSK329 is a potent and selective inhibitor of cardiac-specific kinase TNNI3K (TNNI3 interacting kinase) with IC50 of 10 nM. Synonyms: GSK-329; GSK 329; N-(3,5-dichloro-4-{[6-(methylamino)pyrimidin-4-yl]oxy}phenyl)-N'-[3-(trifluoromethyl)phenyl]urea; N-[3,5-Dichloro-4-[[6-(methylamino)-4-pyrimidinyl]oxy]phenyl]-N-[3-(trifluoromethyl)phenyl]-urea. Grade: 98% by HPLC. CAS No. 1268490-12-5. Molecular formula: C19H14Cl2F3N5O2. Mole weight: 472.2. | |
| GSK3326595 | GSK3326595, also called as EPZ015938, is an orally available and specific inhibitor of protein arginine methyltransferase 5 (PRMT5) that potently inhibits tumor growth in vitro and in vivo in animal models and has entered clinical trials for the treatment of solid tumors and non-Hodgkin's lymphoma. Synonyms: GSK-3326595; GSK 3326595; GSK3326595; EPZ015938; EPZ 015938; EPZ-015938; 6-[(1-acetylpiperidin-4-yl)amino]-N-[(2S)-3-(3,4-dihydro-1H-isoquinolin-2-yl)-2-hydroxypropyl]pyrimidine-4-carboxamide. CAS No. 1616392-22-3. Molecular formula: C24H32N6O3. Mole weight: 452.55. | |
| GSK3326595 | GSK3326595 is a protein arginine methyltransferase 5 (PRMT5) inhibitor. GSK3326595 decreases SARS-CoV-2 infection, inhibits cancer cell proliferation and induces pro-inflammatory macrophage polarization and increases hepatic triglyceride levels without affecting atherosclerosis. GSK3326595 can be used for research of relapsed/refractory mantle cell lymphoma[1][2][3][4][5]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: EPZ015938. CAS No. 1616392-22-3. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 200 mg; 1 g. Product ID: HY-101563. | |
| GSK3326595 (Pemrametostat, EPZ015938) | Pemrametostat (GSK3326595, EPZ015938) is an orally active, potent and selective inhibitor of protein arginine methyltransferase 5 (PRMT5) and potently inhibits tumor growth in vitro and in vivo in animal models. Group: Inhibitors. Alternative Names: EPZ015938. CAS No. 1616392-22-3. Pack Sizes: 5mg. Product ID: S8664. Formula: C24H32N6O3. Smiles: CC(=O)N1CCC(CC1)NC2=NC=NC(=C2)C(=O)NCC(CN3CCC4=CC=CC=C4C3)O. Storage Conditions: 2 years -80 in solvent. |  United States; Europe |
| GSK3368715 | GSK3368715 (EPZ019997) is an orally active, reversible, and S-adenosyl-L-methionine (SAM) uncompetitive type I protein arginine methyltransferases (PRMTs) inhibitor (IC50=3.1 nM (PRMT1), 48 nM (PRMT3), 1148 nM (PRMT4), 5.7 nM (PRMT6), 1.7 nM (PRMT8)). GSK3368715 (EPZ019997) produces a shift in arginine methylation states, alters exon usage, and has strong anti-cancer activity[1]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: EPZ019997. CAS No. 1629013-22-4. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-128717. | |
| GSK3368715 3HCl | GSK3368715 is a potent reversible inhibitor of type I protein arginine methyltransferases (PRMT) with antitumor activity. Synonyms: EPZ019997 3HCl. CAS No. 2227587-26-8. Molecular formula: C20H41Cl3N4O2. Mole weight: 475.92. | |
| GSK3368715 dihydrochloride | GSK3368715 dihydrochloride (EPZ019997 dihydrochloride) is an orally active, reversible, and S-adenosyl-L-methionine (SAM) uncompetitive type I protein arginine methyltransferases (PRMTs) inhibitor (IC50=3.1 nM (PRMT1), 48 nM (PRMT3), 1148 nM (PRMT4), 5.7 nM (PRMT6), 1.7 nM (PRMT8)). GSK3368715 dihydrochloride (EPZ019997 dihydrochloride) produces a shift in arginine methylation states, alters exon usage, and has strong anti-cancer activity[1]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: EPZ019997 dihydrochloride. CAS No. 1628925-77-8. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-128717A. | |
| GSK3368715 dihydrochloride | GSK3368715 dihydrochloride is a reversible, orally active and S-adenosyl-L-methionine (SAM) uncompetitive type I protein arginine methyltransferases (PRMTs) inhibitor with IC50s of 3.1, 48, 1148, 5.7 and 1.7 nM for PRMT1, PRMT3, PRMT4, PRMT6 and PRMT8, respectively. It can change the methylation states of arginine, alter the use of exons, and has strong anticancer activity. Synonyms: EPZ019997 dihydrochloride; N-({3-[4,4-Bis(ethoxymethyl)cyclohexyl]-1H-pyrazol-4-yl}methyl)-N,N'-dimethyl-1,2-ethanediamine dihydrochloride; 1,2-Ethanediamine, N1-[[3-[4,4-bis(ethoxymethyl)cyclohexyl]-1H-pyrazol-4-yl]methyl]-N1,N2-dimethyl-, hydrochloride (1:2). Grade: ≥95%. CAS No. 1628925-77-8. Molecular formula: C20H40Cl2N4O2. Mole weight: 439.46. | |
| GSK343 | GSK343 is a potent, selective inhibitor of EZH2 with cellular activity. GSK343 inhibits EZH2 with an IC50 of 4nM and is over 1000-fold selective for other HMTs except EZH1 (60-fold selectivity). GSK343 inhibits H3K27 methylation in HCC1806 cells with an IC50 of <200nM as measured by immunofluorescence. GSK343 exhibited limited effects on the growth of EOC cells in conventional two-dimensional (2D) culture. In contrast, GSK343 significantly suppressed the growth of EOC cells cultured in 3D matrigel extracellular matrix (ECM), which more closely mimics the tumor microenvironment in vivo. Notably, GSK343 induces apoptosis of EOC cells in 3D but not 2D culture. In addition, GSK343 significantly inhibited the invasion of EOC cells. Synonyms: GSK343; GSK-343; GSK 343. CAS No. 1346704-33-3. Molecular formula: C31H39N7O2. Mole weight: 541.7. | |
| GSK343 | GSK343, a chemical probe, is a highly potent and selective EZH2 inhibitor with an IC50 of 4 nM. Uses: Scientific research. Category: Signaling pathways. CAS No. 1346704-33-3. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-13500. | |
| GSK-345931A | GSK-345931A is an EP(1) receptor antagonist. It is efficient in preclinical models of inflammatory pain. Uses: Inflammatory pain. Synonyms: 869499-38-7(sodium); 6-(5'-chloro-2'-(2-methylpropoxy)(1,1'-biphenyl)-2-yl)- 2-Pyridinecarboxylic acid. Grade: 98%. CAS No. 869534-13-4. Molecular formula: C22H20ClNO3. Mole weight: 381.86. | |
| GSK-345931A sodium | GSK-345931A is an EP(1) receptor antagonist. It is efficient in preclinical models of inflammatory pain. Uses: Inflammatory pain. Synonyms: GSK-345931A sodium; GSK 345931A sodium; GSK345931A sodium; 869534-13-4(Free); 6-(5'-chloro-2'-(2-methylpropoxy)(1,1'-biphenyl)-2-yl)- 2-Pyridinecarboxylic acid sodium salt. Grade: 98%. CAS No. 869499-38-7. Molecular formula: C22H19ClNNaO3. Mole weight: 403.83. | |
| GSK-3484862 | GSK-3484862 is a non-covalent inhibitor for DNA methyltransferase (Dnmt1). GSK-3484862 induces DNA hypomethylation to against cancer. GSK-3484862 mediates dramatic demethylation in murine embryonic stem cells with minimal non-specific toxicity[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2170136-65-7. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 500 mg; 1 g. Product ID: HY-135146. | |
| GSK-356278 | GSK-356278 is a selective Type 4 cyclic nucleotide phosphodiesterase inhibitor. It shows anxiolytic and cognition-enhancing effects and it has the ability to elevate cAMP in various cell types of the central nervous system. No development was reported for phase-I development in Major depressive disorder and Huntington's-disease. Uses: Huntington's disease; major depressive disorder. Synonyms: GSK-356278; GSK356278; GSK 356278; 5-(5-((2,4-dimethyl-5-thiazolyl)methyl)-1,3,4-oxadiazol-2-yl)-1-ethyl-n-(tetrahydro-2H-pyran-4-yl)-1H-Pyrazolo(3,4-b)pyridin-4-amine. Grade: 98%. CAS No. 720704-34-7. Molecular formula: C21H25N7O2S. Mole weight: 439.54. | |
| GSK360A | GSK360A is a potent and orally active HIF-PHD inhibitor with IC50 values of 10, 100, and 126 nM for PHD1, PHD2, and PHD3, respectively. GSK360A activates the HIF-1 alpha pathway and protect the failing heart after myocardial infarction (MI) [1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 931399-19-8. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-123422. | |
| GSK 366 | GSK 366 is a type II kynurenine-3-monooxygenase (KMO) inhibitor with IC50 values of 2.3 nM and 0.7 nM for human KMO and P. fluorescens-KMO (Pf-KMO). GSK 366 binds to KMOs substrate site, prevents productive NADPH association, substrate binding, and FAD hydroperoxy species formation. GSK 366 does not stimulate hydrogen peroxide (H2O2) production and reduces H2O2 levels. GSK 366 can be used for the researches of inflammation and neurological disease, such as acute pancreatitis multiple organ dysfunction syndrome and Alzheimers disease[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1953157-39-5. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-119171. | |
| GSK3685032 | GSK3685032 is a non-time-dependent, non-covalent, first-in-class reversible and selective inhibitor of DNMT1, with IC50 of 0.036 μM. GSK3685032 induces robust loss of DNA methylation, transcriptional activation, and cancer cell growth inhibition. Synonyms: GSK-3685032; GSK 3685032. CAS No. 2170137-61-6. Molecular formula: C22H24N6OS. Mole weight: 420.53. | |
| GSK-3685032 | GSK-3685032 is a non-time-dependent, noncovalently, first-in-class reversible DNMT1-selective inhibitor, with an IC50 of 0.036 μM. GSK-3685032 induces robust loss of DNA methylation, transcriptional activation, and cancer cell growth inhibition[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2170137-61-6. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-139664. | |
| GSK369796 Dihydrochloride | SK369796, also known as N-tert-butylisoquine, shows antimalerial activity with IC50 values of 11.2 nM for 3D7 strain, 12.6 nM for HB3 strain, 17.6 nM for K1 strain. GSK369796 was rationally designed based on chemical, toxicological, pharmacokinetic, and pharmacodynamic considerations and was selected based on excellent activity against Plasmodium falciparum in vitro and rodent malaria parasites in vivo. Synonyms: 2-[(tert-Butylamino)methyl]-5-[(7-chloroquinolin-4-yl)amino]phenol Dihydrochloride; GSK369796 Dihydrochloride; GSK 369796; GSK-369796; GSK369796; N-tert-Butyl isoquine. CAS No. 1010411-21-8. Molecular formula: C20H24Cl3N3O. Mole weight: 428.78. | |
| GSK376501A | GSK376501A is a bio-active chemical compound used for the treatment of type 2 diabetes and hypercholesterolemia. It was developed by GlaxoSmithKline and was once in clinic phase 1, but now it has been terminated. Uses: Gsk376501a is used for the treatment of type 2 diabetes and hypercholesterolemia. Synonyms: GSK-376501A; GSK376501; GSK-376501; 1-[[3,5-bis(2-methoxyethoxy)phenyl]methyl]-3-(4-tert-butylphenyl)indole-2-carboxylic acid; 1H-Indole-2-carboxylic acid, 1-((3,5-bis(2-methoxyethoxy)phenyl)methyl)-3-(4-(1,1-dimethylethyl)phenyl)-. Grade: >98 %. CAS No. 1010412-80-2. Molecular formula: C32H37NO6. Mole weight: 531.64. | |
| GSK3787 | GSK3787 is a selective and irreversible peroxisome proliferator-activated receptor δ (PPARδ) antagonist with pIC50 of 6.6. Uses: Scientific research. Category: Signaling pathways. CAS No. 188591-46-0. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-15577. | |
| GSK 3787 | GSK 3787. Group: Biochemicals. Grades: Purified. CAS No. 188591-46-0. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. |  Worldwide |
| GSK-3787 | GSK-3787 is a potent and selective ligand for PPARdelta with good pharmacokinetic properties. Synonyms: GSK-3787; GSK3787; GSK 3787. CAS No. 188591-46-0. Molecular formula: C15H12ClF3N2O3S. Mole weight: 392.78059. | |
| GSK3987 | GSK3987 is a pan LXRα/β agonist. Synonyms: GSK-3987; GSK 3987; 1-Benzyl-3-[(4-methoxyphenyl)amino]-4-phenyl-1H-pyrrole-2,5-dione. Grade: >98%. CAS No. 264206-85-1. Molecular formula: C24H20N2O3. Mole weight: 384.43. | |
| GSK-3β Antibody [B6C8] | GSK3 beta,GSK3 beta (phospho S9),GSK-3β. Group: Antibodies. Pack Sizes: 20ul. Product ID: F0142. Storage Conditions: -20°C (avoid freeze-thaw cycles), 2 years. | United States; Europe |
| GSK3β-IN-2 | GSK3β-IN-2 (Compound S01) is the inhibitor for GSK3β with an IC50 of 0.35 nM. GSK3β-IN-2 activates Wnt/β-catenin signaling pathway, promotes neurogenesis and neurite growth. GSK3β-IN-2 inhibits Aβ-induced tau hyperphosphorylation at Ser396, reduces the formation of neurofibrillary tangles. GSK3β-IN-2 ameliorates Alzheimer's Disease in zebrafish model[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 3068378-38-8. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-172171. | |
| GSK-3β inhibitor 1 | GSK-3β inhibitor 1 (compound 3a) inhibits GSK-3β with an IC50 of 4.19 nM. GSK-3β inhibitor 1 demonstrates high antidiabetic efficacy in obese Streptozotocin (HY-13753)-treated rats[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 187325-53-7. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-126144. | |
| GSK-3β inhibitor 1 | GSK-3β inhibitor 1 is a glycogen synthase kinase 3β (GSK-3β) inhibitor (IC50 = 4.9 nM) with high antidiabetic efficacy. Synonyms: 3-[(Z)-(2-Pyridinyl)methylene]indoline-2-one; (3Z)-3-(2-pyridinylmethylene)-1,3-dihydro-2H-indol-2-one; (3Z)-3-(pyridin-2-ylmethylene)-1,3-dihydro-2H-indol-2-one; 2H-Indol-2-one, 1,3-dihydro-3-(2-pyridinylmethylene)-, (3Z)-. Grade: ≥95%. CAS No. 187325-53-7. Molecular formula: C14H10N2O. Mole weight: 222.24. | |
| GSK-3β inhibitor 12 | GSK-3β inhibitor 12 is an inhibitor of GSK-3β, an enzyme playing an essential function in T cell differentiation and proliferation. Synonyms: GSK-3beta inhibitor 12; 2-(1H-Indol-3-yl)-N-(5-methylthiazol-2-yl)acetamide. CAS No. 784170-07-6. Molecular formula: C14H13N3OS. Mole weight: 271.34. | |
| GSK-3β inhibitor 2 | GSK-3β inhibitor 2 is a potent, selective and orally active GSK-3β inhibitor (IC50 = 1.1 nM) that can cross the blood-brain barrier and has the potential to treat Alzheimer's disease. Synonyms: 2-(2-(Cyclopropanecarboxamido)pyridin-4-yl)-4-methoxythiazole-5-carboxamide; 2-{2-[(Cyclopropylcarbonyl)amino]-4-pyridinyl}-4-methoxy-1,3-thiazole-5-carboxamide; 5-Thiazolecarboxamide, 2-[2-[(cyclopropylcarbonyl)amino]-4-pyridinyl]-4-methoxy-. Grade: ≥98%. CAS No. 1702428-31-6. Molecular formula: C14H14N4O3S. Mole weight: 318.35. | |
| GSK-3β inhibitor 2 | GSK-3β inhibitor 2 (Compound 3) is a potent, selective and orally active GSK-3β inhibitor with an IC50 of 1.1 nM. GSK-3β inhibitor 2 can cross the blood-brain barrier. GSK-3β inhibitor 2 has the potential for Alzheimer's disease[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1702428-31-6. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-130795. | |
| GSK-3β inhibitor 22 | GSK-3β inhibitor 22 (compound 20o) is a GSK-3β inhibitor with an IC50 of 3.1 nM. GSK-3β inhibitor 22 has the potential of the study of Alzheimer's disease[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1005199-84-7. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg. Product ID: HY-164907. | |
| GSK-3β inhibitor 3 | GSK-3β inhibitor 3 is a potent, selective, irreversible and covalent inhibitor of Glycogen Synthase Kinase 3β (GSK-3β), with an IC50 of 6.6 μM. GSK-3β inhibitor 3 can be used for the research of acute promyelocytic leukemia[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1448990-73-5. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-141480. | |
| GSK-3β inhibitor 3 | GSK-3β inhibitor 3, a potent, selective, irreversible and covalent glycogen synthase kinase 3β (GSK-3β) inhibitor (IC50 = 6.6 μM), is used in the study of acute promyelocytic leukemia. Synonyms: 5-Acryloyl-2-(4-fluorophenyl)-2,3-dihydrobenzo[b][1,4]thiazepin-4(5H)-one; 5-Acryloyl-2-(4-fluorophenyl)-2,3-dihydro-1,5-benzothiazepin-4(5H)-one; 1,5-Benzothiazepin-4(5H)-one, 2-(4-fluorophenyl)-2,3-dihydro-5-(1-oxo-2-propen-1-yl)-; 5-Acryloyl-2,3-dihydro-2-(4-fluorophenyl)-1,5-benzothiazepin-4(5H)-one. Grade: ≥95%. CAS No. 1448990-73-5. Molecular formula: C18H14FNO2S. Mole weight: 327.37. | |
| GSK3β Inhibitor II | GSK3β Inhibitor II is a potent and selective inhibitor of glycogen synthase kinase-3β (GSK3β) with an IC50 value of 390 nM. Synonyms: ?Glycogen Synthase Kinase 3β?? Inhibitor II; Tip-oxadiazole; 4-[5-[[(3-iodophenyl)methyl]thio]-1,3,4-oxadiazol-2-yl]-pyridine; 2-Thio(3-iodobenzyl)-5-(1-pyridyl)-[1,3,4]-oxadiazole. Grade: ≥95%. CAS No. 478482-75-6. Molecular formula: C14H10IN3OS. Mole weight: 395.2. | |
| GSK3β Inhibitor XI | GSK3β inhibitor XI is a cell-permeable, potent and ATP-competitive inhibitor of glycogen synthase kinase 3β (GSK3β; Ki = 25 nM) which is selective for GSK3β over a panel of 79 commonly studied protein kinases. Synonyms: 3-[1-(3-hydroxypropyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-4-(2-pyrazinyl)-1H-pyrrole-2,5-dione. Grade: ≥98%. CAS No. 626604-39-5. Molecular formula: C18H15N5O3. Mole weight: 349.3. | |
| GSK3β Inhibitor XVIII | GSK3β inhibitor XVIII is a cell-permeable, potent and selective inhibitor of glycogen synthase kinase 3β (GSK3β; IC50 = 64 nM). Synonyms: [2-chloro-4-[[4-(2-thienyl)-2-pyrimidinyl]amino]phenyl](4-methyl-1-piperazinyl)-methanone. Grade: ≥98%. CAS No. 1139875-74-3. Molecular formula: C20H20ClN5OS. Mole weight: 413.9. | |
| GSK3β-peptide | GSK3β-peptide is a substrate mimetic peptide of glycogen synthase kinase 3-β (GSK3-β) that can bind to the active site of GSK3-β and mimic the behavior of a real substrate. GSK3β-peptide can be used to develop substrate mimetic inhibitors of Akt as potential anticancer drugs[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 496856-73-6. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P10605. | |
| GSK-3b Inhibitor XI | GSK-3b Inhibitor XI (Compound 33) is a potent and selective GSK3β inhibitor, with a Ki value of 25 nM. GSK-3b Inhibitor XI increases glycogen synthase (GS) activity. GSK-3b Inhibitor XI can be used for research on type 2 diabetes and Alzheimers disease[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 626604-39-5. Pack Sizes: 1 mg. Product ID: HY-112388. | |
| GSK-3/CDK5/CDK2-IN-1 | GSK-3/CDK5/CDK2-IN-1, an inhibitor of CDK5, CDK2 and GSK-3, can be used in the study of cancer and neurodegenerative diseases. (Extracted from patent WO2002010141A1, example 9a). Synonyms: 2-Naphthaleneacetamide, N-[1-[cis-3-(acetylamino)cyclobutyl]-1H-imidazol-4-yl]-; N-(1-((1s,3s)-3-acetamidocyclobutyl)-1H-imidazol-4-yl)-2-(naphthalen-2-yl)acetamide; N-[1-(cis-3-Acetamidocyclobutyl)-1H-imidazol-4-yl]-2-(2-naphthyl)acetamide. Grade: ≥98%. CAS No. 395074-72-3. Molecular formula: C21H22N4O2. Mole weight: 362.42. | |
| GSK3-IN-3 | GSK3-IN-3 is a mitophagy inducer, inducing Parkin-dependent mitophagy. GSK3-IN-3 is also a GSK-3 inhibitor with an IC50 value of 3.01 μM. GSK3-IN-3 is non-ATP nor substrate competitive and is neuroprotective against 6-OHDA[1][2][3]. Uses: Scientific research. Category: Signaling pathways. CAS No. 331963-27-0. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-153089. | |
| GSK-3 inhibitor 1 | GSK-3 inhibitor 1 is a potent GSK-3 inhibitor. Grade: >98%. CAS No. 603272-51-1. Molecular formula: C22H17ClFN5O2. Mole weight: 437.85. | |
| GSK-3 Inhibitor, AR-A014418, (N-[(4-Methoxyphenyl)methyl]-N-(5-nitro-2-thiazolyl)urea) | Cell-permeable. A selective glycogen synthase kinase 3 (GSK-3) inhibitor (IC50 = 104nm). Inhibition is competitive with respect to ATP (Ki = 38nm). Exhibits specificity for GSK-3 over cdk2 and cdk5 (IC50 values are > 100 =um) and over 26 other kinases. Inhibits b-amyloid-mediated neurodegeneration in hippocampal slices. Group: Biochemicals. Grades: Highly Purified. Pack Sizes: 2mg. Molecular Formula: C??H??N?O?S. US Biological Life Sciences. | Worldwide |
| GSK 3 Inhibitor IX | GSK 3 Inhibitor IX (6-Bromoindirubin-3'-oxime; BIO) is a potent, selective, reversible and ATP-competitive inhibitor of GSK-3α/β and CDK1-cyclinB complex with IC50s of 5 nM/320 nM/80 nM for (GSK-3α/β)/CDK1/CDK5, respectively. Uses: Scientific research. Category: Signaling pathways. Alternative Names: 6-Bromoindirubin-3'-oxime; BIO; MLS 2052. CAS No. 667463-62-9. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-10580. | |
| GSK-3 Inhibitor XIII | An inhibitor of GSK-3. Synonyms: (5-Methyl-1H-pyrazol-3-yl)-(2-phenylquinazolin-4-yl)amine. Grade: >98%. CAS No. 404828-14-4. Molecular formula: C18H15N5. Mole weight: 301.3. | |
| GSK3 Inhibitor XIII | GSK3 Inhibitor XIII is a potent and ATP-competitive inhibitor of glycogen synthase kinase 3 (GSK3). Synonyms: Glycogen Synthase Kinase 3 Inhibitor XIII; 5,6,7,8-tetrahydro-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl-4-quinazolinamine. Grade: ≥98%. CAS No. 404828-08-6. Molecular formula: C18H19N5. Mole weight: 305.4. | |
| GSK3 Inhibitor XV | GSK3 inhibitor XV is a racemic mixture of (R)-GSK3 inhibitor XV and (S)-GSK3 inhibitor XV. (R)-GSK3 inhibitor XV inhibits glycogen synthase kinase (GSK) 3α and β with IC50 values of 0.35 and 0.55 nM respectively. (S)-GSK3 inhibitor XV is less potent than the (R)-GSK3 inhibitor XV. Synonyms: [11-bromo-9-hydroxypyrido[2,3-a]pyrrolo[3,4-c]carbazole-5,7(1H,6H)-dionato-κN1,κN12]carbonyl[(1,2,3,4,5-η)-1-(methoxycarbonyl)-2,4-cyclopentadien-1-yl]-ruthenium. Grade: ≥98%. CAS No. 936112-69-5. Molecular formula: C25H14BrN3O6Ru. Mole weight: 633.40. | |
| GSK4027 | GSK4027 is a potent and selective inhibitor of p300/CBP-associated factor (PCAF)/general control nonderepressible 5 (GCN5) bromodomain (Ki = 1.4 nM; IC50 = 60 nM in a chromatin engagement assay). Synonyms: 4-bromo-2-methyl-5-[[(3R,5R)-1-methyl-5-phenyl-3-piperidinyl]amino]-3(2H)-pyridazinone. Grade: ≥95%. CAS No. 2079896-25-4. Molecular formula: C17H21BrN4O. Mole weight: 377.3. | |
| GSK 4027 | GSK 4027 is a chemical probe for the PCAF/GCN5 bromodomain with an pIC50 of 7.4±0.11 for PCAF in a time-resolved fluorescence resonance energy transfer (TR-FRET) assay. Uses: Scientific research. Category: Signaling pathways. CAS No. 2079896-25-4. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-101027. | |
Our database is helping our users find suppliers everyday.
